| Name | Title | Contact Details |
|---|
The DePuy Synthes Companies offer the world’s most comprehensive portfolio of orthopaedic and neuro products and services for joint reconstruction, trauma, spine, sports medicine, neuro, cranio-maxillofacial, power tools and biomaterials. Each of the companies that comprise DePuy Synthes Companies has a celebrated history, and each has evolved to meet the needs of the changing orthopaedics and neuro marketplace. The history that weaves the fabric of the DePuy Synthes Companies is one that is rich with innovation and demonstrates sustained leadership in an ever-changing landscape of patient and professional needs. The content from the DePuy Synthes Companies LinkedIn page is informational only. This content is not a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician with questions regarding a medical condition. Reliance on information provided herein is at your own risk. Comments which are off-topic, offensive, or promotional, are prohibited. Neither DePuy Synthes Companies nor any of its operating companies are responsible for third-party materials appearing on the DePuy Synthes Companies page, including but not limited to linked third-party videos, linked third-party sites, and third-party advertisements. DePuy Synthes Companies does not control or endorse this third-party content and makes no representations regarding its accuracy.
Cardiac Diagnostic Services is a Independence, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baxter Healthcare is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diopsys Inc is a Pine Brook, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. FDA-cleared GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) for patients undergoing brain tumor removal surgery of newly diagnosed malignant and recurrent brain tumors. This "one-and-done" treatment eliminates the need for one to six weeks of daily external beam radiation therapy, allowing patients to go about their daily lives without the burden of additional trips to the hospital or clinic for ongoing treatment. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 95 hospitals, with more centers being added each month.